400-75-9

Basic information

• Product Name: 2-(Trifluoromethyl)-1-iodo-4-nitrobenzene
• Synonyms: 2-(Trifluoromethyl)-1-iodo-4-nitrobenzene;3-(Trifluoromethyl)-4-iodonitrobenzene;1-Iodo-4-nitro-2-(trifluoromethyl)benzene;4-Iodo-3-trifluoromethylnitrobenzene;1-Iodo-4-nitro-2-(trifluoromethyl)
• CAS NO: 400-75-9
• Molecular Formula: C₇H₃F₃INO₂
• Molecular Weight: 317.01
• Mol File: 400-75-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 82 °C
• Boiling Point: 273.9±40.0 °C(Predicted)
• Appearance: /
• Density: 2.020±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-(Trifluoromethyl)-1-iodo-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Trifluoromethyl)-1-iodo-4-nitrobenzene(400-75-9)
• EPA Substance Registry System: 2-(Trifluoromethyl)-1-iodo-4-nitrobenzene(400-75-9)

Safety Data

• Hazardous Substances Data: 400-75-9(Hazardous Substances Data)

Usage

General Description

2-(Trifluoromethyl)-1-iodo-4-nitrobenzene is a chemical compound with the molecular formula C7H4F3INO2. It is a yellow crystalline powder that is commonly used in pharmaceutical and agrochemical industries as an intermediate for the synthesis of various compounds. This chemical is known for its trifluoromethyl and nitro functional groups, which make it a versatile building block for organic synthesis. It is a potential reagent for the introduction of the trifluoromethyl group into various organic molecules due to its strong electron-withdrawing properties. Additionally, the iodine atom in the compound makes it a useful molecule for the preparation of radiolabeled compounds for use in medical imaging and research. However, it is important to handle this chemical with caution, as it is toxic and may cause irritation to the skin and eyes upon contact.

Upstream product

• 121-01-7 4-nitro-2-trifluoromethyl-aniline 
• 395-68-6 N-(4-nitro-2-(trifluoromethyl)phenyl)acetamide 
• 344-62-7 N-[2-(trifluoromethyl)phenyl]acetamide 

Downstream Products

• 1978-20-7 3,4-bis(trifluoromethyl)nitrobenzene 
• 341-58-2 2,2'-bis(trifluoromethyl)benzidine 
• 19230-50-3 2-iodo-5-nitro-benzoic acid 
• 794-56-9 1-(trifluoroacetamido)-3,4-bis(trifluoromethyl)benzene 
• 2965-07-3 3,4-Bis(trifluoromethyl)aniline 
• 1007401-61-7 4-nitro-1-(oct-1-ynyl)-2-(trifluoromethyl)benzene 
• 1416958-13-8 C₃₂H₄₃F₃N₂O₅ 
• 1088699-54-0 4-octyl-3-(trifluoromethyl)aniline 
• 155403-06-8 3-(trifluoromethyl)-4-iodobenzenamine 

Relevant articles and documents

Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors

Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto - enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited-marked antiretroviral activity. Here, we show the synthesis and the detailed structure - activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3,3- dimethylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nMin the strand transfer assay and an ED50 of 0.6 nMin the antiviral assay, and 6-(3-chloro-2-fluorobenzyl) -1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid 49, which had an IC50 of 7.2 nMand an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrasecatalyzed strand transfer processes than 3′-processing reactions, as is the case with the keto - enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.